Li, J.; Pohl, L.; Schüler, J.; Korzeniewski, N.; Reimold, P.; Kaczorowski, A.; Hou, W.; Zschäbitz, S.; Nientiedt, C.; Jäger, D.;
et al. Targeting the Proteasome in Advanced Renal Cell Carcinoma: Complexity and Limitations of Patient-Individualized Preclinical Drug Discovery. Biomedicines 2021, 9, 627.
https://doi.org/10.3390/biomedicines9060627
AMA Style
Li J, Pohl L, Schüler J, Korzeniewski N, Reimold P, Kaczorowski A, Hou W, Zschäbitz S, Nientiedt C, Jäger D,
et al. Targeting the Proteasome in Advanced Renal Cell Carcinoma: Complexity and Limitations of Patient-Individualized Preclinical Drug Discovery. Biomedicines. 2021; 9(6):627.
https://doi.org/10.3390/biomedicines9060627
Chicago/Turabian Style
Li, Jielin, Laura Pohl, Julia Schüler, Nina Korzeniewski, Philipp Reimold, Adam Kaczorowski, Weibin Hou, Stefanie Zschäbitz, Cathleen Nientiedt, Dirk Jäger,
and et al. 2021. "Targeting the Proteasome in Advanced Renal Cell Carcinoma: Complexity and Limitations of Patient-Individualized Preclinical Drug Discovery" Biomedicines 9, no. 6: 627.
https://doi.org/10.3390/biomedicines9060627
APA Style
Li, J., Pohl, L., Schüler, J., Korzeniewski, N., Reimold, P., Kaczorowski, A., Hou, W., Zschäbitz, S., Nientiedt, C., Jäger, D., Hohenfellner, M., Duensing, A., & Duensing, S.
(2021). Targeting the Proteasome in Advanced Renal Cell Carcinoma: Complexity and Limitations of Patient-Individualized Preclinical Drug Discovery. Biomedicines, 9(6), 627.
https://doi.org/10.3390/biomedicines9060627
